INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
People with advanced and metastatic non-small cell lung cancer (NSCLC) that responds to targeted therapies or check point inhibitors now routinely survive for three or four years after diagnosis, and a lucky few live substantially longer. Chemotherapy and targeted therapy are both treatments that attacks cancer cells. Targeted therapy is less toxic to healthy cells than chemotherapy. Both options are often done in conjunction with other treatments, such as radiation. Before you have some types of targeted drugs you might need to have tests using some of your cancer cells or a blood sample. This is to find out whether the treatment is likely to work. These tests look for changes in certain proteins or genes. Your cancer specialist can tell you if this applies to your treatment.
"A REVIEW ON: “TARGETED CANCER THERAPY & THEIR DRUGS”", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.7, Issue 10, page no.285-296, October-2022, Available :http://www.ijnrd.org/papers/IJNRD2210161.pdf
Downloads:
000118754
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn